Immuron (IMRN) Cost of Revenue (2016 - 2024)
Immuron (IMRN) recorded quarterly Cost of Revenue of -$874530928.1 billion in Q4 2024, down 112808930498813.45% quarter-over-quarter from $775232.0 in Q4 2023, and down 112808930498813.45% on a YoY basis from N/an in Q1 2024.
Immuron (IMRN) Cost of Revenue (2016 - 2024) Analysis & Trends
Immuron's Cost of Revenue history runs 9 years deep, the most recent figure standing at -$874530928.1 billion for Q4 2024.
- In Q4 2024, Cost of Revenue fell 112808930498813.45% year-over-year to -$874530928.1 billion; the TTM figure through Dec 2024 stood at -$874530928.1 billion (down 90126392551963.98% YoY), while the FY2025 annual figure was $312370.5, down 69.59% from the prior year.
- Cost of Revenue was -$874530928.1 billion for Q4 2024 at Immuron, down from $775232.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $775232.0 in Q4 2023 to a low of -$874530928.1 billion in Q4 2024.
- Historically, Cost of Revenue has averaged -$109316366.0 billion across 5 years, with a median of $19690.2 in 2023.
- The sharpest annual moves came in 2021 and 2024: Cost of Revenue soared 5568778.93% in 2021, then plunged 112808930498813.45% in 2024.
- A 5-year view of Cost of Revenue shows it stood at $0.01 in 2020, then jumped by 5568778.93% to $508.16 in 2021, then soared by 30545.09% to $155726.0 in 2022, then jumped by 397.82% to $775232.0 in 2023, then slumped by 112808930498813.45% to -$874530928.1 billion in 2024.
- The last three Cost of Revenue figures came in at -$874530928.1 billion (Q4 2024), $775232.0 (Q4 2023), and $14310.9 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -874,530,928.08 Bn |
| Dec 31, 2024 | -874,530,928.08 Bn |
| Dec 31, 2023 | 775,232.00 |
| Dec 31, 2023 | 775,232.00 |
| Jun 30, 2023 | 14,310.93 |
| Jun 30, 2023 | 14,310.93 |
| Dec 31, 2022 | 155,726.00 |
| Dec 31, 2022 | 155,726.00 |
| Jun 30, 2022 | 25,069.39 |
| Jun 30, 2022 | 25,069.39 |
| Dec 31, 2021 | 508.16 |
| Dec 31, 2021 | 508.16 |
| Dec 31, 2020 | 0.01 |
| Dec 31, 2020 | 0.01 |
| Jun 30, 2020 | 45,879.44 |
| Jun 30, 2020 | 45,879.44 |
| Dec 31, 2019 | 4,351.98 |
| Dec 31, 2019 | 4,351.98 |
| Dec 31, 2018 | 231,479.00 |
| Dec 31, 2018 | 231,479.00 |